PATIENTS IN SCOTLAND WITH AN ADVANCED FORM OF PROSTATE CANCER CAN NOW ACCESS LYNPARZA (OLAPARIB) WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE WITHOUT A BIOMARKER TEST
To improve long-term health outcomes for people living with rheumatoid arthritis it is imperative to get active disease under control as soon as possible.
AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain for the treatment of symptomatic chronic heart failure (HF) in patients with HF and a left ventricular ejection fraction (LVEF)
STRICTLY EMBARGOED UNTIL Tuesday 6 September 2022 00:01 BST LYNPARZA (olaparib) APPROVED IN GREAT BRITAIN AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER First and only approved medicine in Great Britain which targets germline BRCA mutations in pati.